Kura Oncology, Inc.

This early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…

This study tests a new oral drug, ziftomenib, combined with the standard drug imatinib in adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. The goal is to see if the combination is safe and can shrink or stabilize tumors. About …

This early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…

This early-stage study tests a new drug called KO-2806 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors, either alone or combined with other therapies. About 300 adults wi…

This study tests whether adding an experimental drug called ziftomenib to standard chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) live longer or achieve remission. About 1,300 adults with untreated AML and certain gene changes will receive …